Pluripotent mesenchymal stem cells and methods of use thereof
Patent 5827735 Issued on October 27, 1998. Estimated Expiration Date: 
May 20, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
May 20, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesNeomorphogenesis of cartilage in vivo from cell culture Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells Method for treating connective tissue disorders Muscle morphogenic protein and use thereof Human mesenchymal stem cells Patent #: 5486359 InventorsAssigneeApplicationNo. 650420 filed on 05/20/1996US Classes:435/325, ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE435/349, Avian cell, per se435/380Releasing bound or adhered cell using proteaseExaminersPrimary: Saunders, DavidAttorney, Agent or FirmInternational ClassesC12N 005/00C12N 005/02 AbstractA scar inhibitory factor protein isolate from mammalian basement membranes is provided that inhibits lineage commitment and differentiation of stem cells in vitro and in vivo. The protein isolate is characterized by its ability to inhibit stem cell commitment to a fibroblastic-scar phenotype without killing the cells, thus allowing their differentiation into normal tissue phenotypes. SIF thus limits the amount of scar tissue formation at the site of delivery, while maximizing the potential for the stem cells to differentiate into other tissue phenotypes (muscle, cartilage, bone, fat, etc.). Therefore, it is useful in treating numerous disorders and injuries that currently result in scar tissue or fibrous adhesion formation. The protein isolate can be administered in various modalities in vivo, i.e., as a transdermal patch, incorporated into wound dressings, incorporated into absorbable suture material, incorporated into a bioerodible polymer matrix by itself or interspersed with differentiation factors near the site of tissue injury, sprayed onto prosthetic implants, and can be administered directly to cells cultured in vitro.Other References
Field of SearchAvian cell, per seImmunoglobulin or antibody binds an oligosaccharide structure other than nucleic acid Using mechanical means (e.g., trituration, etc.) Releasing bound or adhered cell using protease Solid support and method of culturing cells on said solid support Contains a growth factor or growth regulator ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE |
| ||||||||||||||
